Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug

Regeneron Pharmaceuticals

08/12/2025 12:26

** Shares of Ocular Therapeutix OCUL.O rise 13.5% to $14.28 in premarket trading

** OCUL says its plans to submit a marketing application for its experimental eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026

** Wet AMD is a leading cause of vision loss in older adults, marked by abnormal blood vessel growth in the retina

     ** Company says the study is designed to show superiority over Regeneron Pharma's REGN.O Eylea and aligns with recent FDA guidance that a single, well-controlled trial may support approval

** As of last close, stock up 47.3% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))